MBTPS1 and cancer: Numerous evidence has suggested Sphk1 as a promising target for cancer therapy for the following reasons: Sphk1 is overexpressed in various types of tumors and acts as an oncogene, and Sphk1 can be induced by growth factors, cytokines, mitogens, and carcinogens, and subsequently leads to the increases of S1P; in turn, S1P potentially stimulates cancer angiogenesis, mobility, invasion, and metastasis.